The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR+/HER2- advanced breast cancer: A phase Ib study.
 
Qingyuan Zhang
No Relationships to Disclose
 
Pin Zhang
No Relationships to Disclose
 
Min Yan
No Relationships to Disclose
 
Xi Yan
Research Funding - Jiangsu Hengrui Pharmaceuticals
 
Xian Wang
No Relationships to Disclose
 
Yuanting Gu
No Relationships to Disclose
 
Xiujuan Qu
No Relationships to Disclose
 
Shaorong Li
Employment - Jiangsu Hengrui Pharmaceuticals
 
Guoying Xu
Employment - Jiangsu Hengrui Pharmaceuticals
 
Wenhui Yang
Employment - Jiangsu Hengrui Pharmaceuticals
 
Xiaoyu Zhu
Employment - Jiangsu Hengrui Pharmaceuticals
 
Xiaojing Zhang
Employment - Jiangsu Hengrui Pharmaceuticals
 
Binghe Xu
Speakers' Bureau - AstraZeneca; Eisai; Pfizer; Roche
Research Funding - Jiangsu Hengrui Medicine (Inst)